Boehringer completes major investment for respiratory diseases

Just as the next-generation Respimat inhaler hits the first European markets, Boehringer Ingelheim has completed the investment of 105 million euros ($118 million) to expand associated production operations at its sites in Dortmund and Ingelheim.

Sufficient capacity is now available for the next generation of this successful medical device, said the German family-owned pharma major.

“The volume of the investment and further development of Respimat demonstrate Boehringer Ingelheim’s long-term commitment to combating serious respiratory diseases,” explains country manager Dr Sabine Nikolaus, adding: “This also underscores our commitment to Germany as a production location.”